MacuCoach

MacuCoach™: Voice-First AI Companion for Vision Health & Age-Related Macular Degeneration

Translating multi-omic insights and clinical guidelines into personalized digital health support for older adults living with early-to-intermediate AMD.

Supported by the American Macular Degeneration Foundation (AMDF)

Bridging the Home-to-Clinic Gap in Age-Related Macular Degeneration

Age-Related Macular Degeneration (AMD) impacts over 20 million people across North America and represents a leading cause of central vision loss[cite: 185, 186]. While standard clinical guidelines—including AREDS2 formula supplementation, Mediterranean dietary quality, regular physical movement, and home vision monitoring—are proven to reduce AMD progression risk [cite: 199, 203], patients frequently struggle to sustain these daily routines independently at home[cite: 198, 202].

MacuCoach™ is an AI-powered, non-commercial digital health companion engineered specifically to provide continuous, low-friction behavioral care and health literacy support between clinical visits[cite: 156, 157, 213, 220].

Key Technical & Accessibility Pillar Engine

📷 Multimodal Vision AI Meal & Label Analysis

Utilizing advanced Google Gemini Vision AI models, MacuCoach™ enables participants to capture plate photos or package nutrition labels in real time. The engine evaluates carotenoid density (lutein, zeaxanthin), omega-3 content, and Mediterranean diet adherence, providing personalized, non-prescriptive dietary recommendations ("Next-Time Level Up") to support retinal health.

🗣️ Voice-First Low-Vision Ergonomics

Designed specifically for individuals facing visual fatigue, scotomas, or contrast sensitivity loss. MacuCoach™ features a complete Voice-First interface with speech-to-text input and natural voice synthesis ("Listen" read-aloud) for all daily cards, AI coach notes, and micro-learning modules.

🛡️ Dynamic Lifestyle Shield & 4-Card Daily Routine

MacuCoach™ simplifies complex lifestyle guidance into an intuitive, 2-minute daily routine[cite: 167, 168]:

  • Card 1 (Tailored): Standard AREDS2 Supplement Check (Cohort A) or Morning Eye-Health Check (Cohort B)[cite: 216].
  • Card 2: Mediterranean Nutrition & Carotenoid Meal Confirmation[cite: 249].
  • Card 3: Active Walk & Moderate Physical Movement Guide (Talk-Test safety enabled)[cite: 166].
  • Card 4 (Profile-Gated): Ocular Rest & Hydration or Smoking Cessation Check.

🔬 Multi-Omic & Bio-Vault Architecture

Engineered to cross-reference multi-omic baseline factors—including polygenic risk variants (CFH, ARMS2), ocular structure metrics, systemic metabolic factors, and vitals [cite: 209, 245, 247, 252]—within a security-first, end-to-end encrypted Bio-Vault architecture compliant with HIPAA and PIPEDA standards[cite: 226, 227, 228].

Unbranded & Standard Guidance Commitment

MacuCoach™ is completely unbranded and operates independently of any commercial product or supplement manufacturer. The platform promotes only globally recognized clinical care guidelines: standard AREDS2 formula supplements as prescribed by eye clinicians, evidence-based Mediterranean dietary patterns, general physical movement, and routine home vision self-monitoring (Amsler Grid).

MacuCoach™ Daily Dashboard — Featuring the Voice-First interface

MacuCoach™ Daily Dashboard — Featuring the Voice-First interface, high-contrast low-vision ergonomics, and the 4-card daily routine (Vision Check, AREDS2/Meds, Mediterranean Nutrition, and Movement).


 

MacuCoach Gemini Vision AI Meal Analysis Screen

Multimodal Gemini Vision AI: Real-time camera capture for meal and plate analysis, providing personalized, non-prescriptive Mediterranean dietary insights ("Next-Time Level Up") for macular health.


Longitudinal Analytics Ecosystem — Multi-year tracker

Longitudinal Analytics Ecosystem: Multi-year tracking of vision self-checks, lifestyle adherence trends, and encrypted multi-omic risk metrics.

  

Pilot Study & Research Collaboration

Persavita is currently planning a 12-week feasibility and usability pilot study in collaboration with the American Macular Degeneration Foundation (AMDF) evaluating MacuCoach™ in older adults with early-to-intermediate AMD.

To request our pilot study protocol summary,
clinical briefs, or demo access, please contact:

Dr. Mahmood Piraee, PhD, PharmD — Founder & CEO
📧 mpiraee@persavita.com